First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial (2018)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1200/JCO.2017.76.7863
- Subjects: NEOPLASIAS MAMÁRIAS; QUIMIOTERAPIA ADJUVANTE; INIBIDORES DE ENZIMAS; RECEPTORES DE ESTEROIDES; METÁSTASE NEOPLÁSICA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Alexandria
- Date published: 2018
- Source:
- Título: Journal of clinical oncology
- ISSN: 0732-183X
- Volume/Número/Paginação/Ano: v. 36, n. 28, p. 2826-2835, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
RIMAWI, Mothaffar et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, v. 36, n. 28, p. 2826-2835, 2018Tradução . . Disponível em: https://doi.org/10.1200/JCO.2017.76.7863. Acesso em: 15 fev. 2026. -
APA
Rimawi, M., Ferrero, J. -M., Haba-rodriguez, J. de la, Poole, C., Placido, S. D., Osborne, C. K., et al. (2018). First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, 36( 28), 2826-2835. doi:10.1200/JCO.2017.76.7863 -
NLM
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.[citado 2026 fev. 15 ] Available from: https://doi.org/10.1200/JCO.2017.76.7863 -
Vancouver
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.[citado 2026 fev. 15 ] Available from: https://doi.org/10.1200/JCO.2017.76.7863 - Eficacia, tolerabilidade e aceitabilidade do estradiol transdermico no tratamento dos sintomas da menopausa
- Sindrome do climaterio: conceito, importancia e epidemiologia
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
- Câncer da mama: quadro clínico, diagnóstico e estadiamento
- Mastite puerperal
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Galactorreia: sindrome hiperprolactinemica
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
Informações sobre o DOI: 10.1200/JCO.2017.76.7863 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
